Three-year clinical outcomes of the novel sirolimus-eluting bioresorbable scaffold for the treatment of de novo coronary artery disease: A prospective patient-level pooled analysis of NeoVas trials.

Abstract

OBJECTIVES:

We aimed to evaluate the long-term outcomes of the novel NeoVas sirolimus-eluting bioresorbable scaffold (BRS) for the treatment of de novo coronary artery disease.

BACKGROUND:

The long-term safety and efficacy of the novel NeoVas BRS are still needed to be elucidated.

METHODS:

A total of 1103 patients with de novo native coronary lesions for coronary stenting were enrolled. The primary endpoint of target lesion failure (TLF) was defined as a composite of cardiac death (CD), target vessel myocardial infarction (TV-MI), or ischemia-driven-target lesion revascularization (ID-TLR).

RESULTS:

A three-year clinical follow-up period was available for 1,091 (98.9%) patients. The cumulative TLF rate was 7.2% with 0.8% for CD, 2.6% for TV-MI, and 5.1% for ID-TLR. Additionally, 128 (11.8%) patient-oriented composite endpoint and 11 definite/probable stent thromboses (1.0%) were recorded.

CONCLUSIONS:

The extended outcomes of the NeoVas objective performance criterion trial demonstrated a promising 3-year efficacy and safety of the NeoVas BRS in low-risk patients with low complexity in terms of lesions and comorbidities.

• Authors: Xiaozeng Wang, Yang Li, Guosheng Fu, Bo Xu, Yujie Zhou, Xi Su, Huiliang Liu, Zheng Zhang, Bo Yu, Ling Tao, Qun Zheng, Lang Li, Kai Xu, Yaling Han, NeoVas OPC Investigators
• Journal: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (Catheter Cardiovasc Interv) Vol. 101 Issue 6 Pg. 967-972 (05 2023) ISSN: 1522-726X [Electronic] United States
• PMID: 36881746 (Publication Type: Journal Article)
• Copyright: © 2022 Wiley Periodicals LLC.

Chemical References

• Sirolimus
• Cardiovascular Agents

Topics

• Humans
• Coronary Artery Disease (therapy, drug therapy)
• Sirolimus (adverse effects)
• Absorbable Implants
• Prospective Studies
• Treatment Outcome
• Drug-Eluting Stents
• Myocardial Infarction (etiology, drug therapy)
• Percutaneous Coronary Intervention (adverse effects)
• Cardiovascular Agents (adverse effects)